As a team of fine chemical manufacturers in India, WBCIL offers this chemical compound that is used in the pharmaceutical and medical industries to treat iron deficiency or anemia. This is a macromolecular ferric hydroxide carbohydrate complex that is a composition of carboxymaltose and iron hydroxide. It is a water-soluble iron salt used for increasing red blood cells in the body to support the oxygen flow throughout the body. The chemical is widely used in anti-anemic medicines in the industry.
Being one of the leading chemical manufacturing companies in India, WBCIL offers quality FERRIC CARBOXYMALTOSE for medicine and pharmaceutical uses.
FERRIC CARBOXYMALTOSE is a great source of iron, and the compound is used to treat people with anemia. It is a state of iron deficiency in the body that reduces the hemoglobin count. The compound belongs to the anti-anemic medicines group. It is usually taken as a supplement for iron deficiency in the body which cannot be fulfilled by food consumption. As one of the Best Chemical Industries In India, WBCIL offers the best quality of this compound for medical and pharmaceutical uses. WBCIL is one of the leading Industrial Chemical Suppliers In India that offers pharmaceutical and chemical compounds that precisely meet all the bars of industrial criteria.
The compound is not widely used in the food industry as it is specially developed and used for the pharmaceutical industry only.
ABSTRACT The effectiveness of intravenous ferric carboxymaltose (FCM) in quickly increasing normal hemoglobin concentration and replenishing body iron reserves up to 6–12 wk is known; however, its long-term effectiveness is unknown. In this study conducted in northern India during August...Read more
Abstract Background Perioperative anemia is common in cardiac surgery. Few studies investigated the effect of postoperative intravenous (IV) iron supplementation and were mostly inconclusive. Methods Design: A randomized single-center, double-blind, placebo-controlled, parallel-group trial. Participants: 195 non-anemic patients were recruited from...Read more
Author links open overlay panel Nanja Bevers MD 1, Els Van de Vijver PhD, MD 2, Arta Aliu 1, Ashkan Rezazadeh Ardabili MD 3, Philippe Rosias MD, PhD 1, Janneke Stapelbroek MD, PhD 4, Imke A. Bertrams Maartens MD 5,...Read more
Abstract Introduction: Iron deficiency (ID) is associated with worse outcomes in patients with heart failure (HF). In adults with HF and ID, intravenous (IV) iron replacement therapy (IRT) improves HF outcomes and is the first-line therapy for ID because oral...Read more
Background: Iron deficiency is common in patients with heart failure (HF) and is associated with reduced exercise capacity and poor outcomes. Whether correction of iron deficiency with (intravenous) ferric carboxymaltose (FCM) affects peak oxygen consumption [peak VO2], an objective measure...Read more
Introduction: PAH is a progressive disease with limited prognosis. Iron deficiency (ID) correlates in PAH patients with disease severity and mortality. Oral iron resorption is impaired by hepcidine in PAH. In a former pilot study, we could demonstrate a short-term...Read more